Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunodeficiency and tuberculosis].

Christophe Billy1, Christian Perronne

  • 1Service des maladies infectieuses et tropicales Hôpital Raymond-Poincaré 92380 Garches.

La Revue Du Praticien
|February 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Lesgards et al. Do Long COVID and COVID Vaccine Side Effects Share Pathophysiological Picture and Biochemical Pathways? <i>Int. J. Mol. Sci.</i> 2025, <i>26</i>, 7879.

International journal of molecular sciences·2025
Same author

Do Long COVID and COVID Vaccine Side Effects Share Pathophysiological Picture and Biochemical Pathways?

International journal of molecular sciences·2025
Same author

Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial.

The Journal of antimicrobial chemotherapy·2024
Same author

Cost of illness in patients with post-treatment Lyme disease syndrome in Belgium.

European journal of public health·2023
Same author

A Restructured Hospital Into a One-Building Organization for COVID-19 Patients: A Resilient and Effective Response to the Pandemic.

Frontiers in public health·2022
Same author

Identifying SARS-COV-2 infected patients through canine olfactive detection on axillary sweat samples; study of observed sensitivities and specificities within a group of trained dogs.

PloS one·2022
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Medical conditions can weaken the immune system, increasing tuberculosis risk. Managing tuberculosis in immunocompromised patients, especially those with human immunodeficiency virus (HIV), requires expert care to prevent serious consequences.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Public Health

Context:

  • Medical conditions can significantly alter immune responsiveness.
  • Immunodeficiency predisposes individuals to opportunistic infections like tuberculosis.
  • Human immunodeficiency virus (HIV) infection is a primary driver of immunodeficiency and increased tuberculosis susceptibility.

Purpose:

  • To highlight the complexity and serious consequences of managing tuberculosis in immunocompromised patients.
  • To emphasize the critical role of human immunodeficiency virus (HIV) infection in tuberculosis pathogenesis.
  • To advocate for expert-led, multidisciplinary care for immunodeficiency-related tuberculosis.

Summary:

  • Tuberculosis (TB) risk is elevated in individuals with compromised immune systems due to various medical conditions.

Related Experiment Videos

  • Treatment failure in immunodeficiency-related TB carries severe clinical and public health implications.
  • Co-management by specialists in both immunodeficiency and tuberculosis is crucial for optimal patient outcomes.

    • Impact:

    • Improved understanding of TB risk factors in immunocompromised populations.
    • Enhanced clinical strategies for managing complex TB cases.
    • Reduced public health burden associated with TB treatment failure in vulnerable groups.